ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
05/19/2022
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Case type
Recorded events
Latest update
Classification
Trademark type
Nice classes
Filing date
Registration date
Expiration date
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Structured fields from the responsible authority and the official record.
Status date
Last transaction
Responsible office
Status code
Official register
Drawing code
Owner type
Owner location
Examiner
Law office
Current location
Mark description
The mark consists of stylized letters "ITM" with two dots coming from the top of the "i" all positioned above the phrase "PASSION FOR PRECISION".
Holders
Representatives
KARI MOYER-HENRY LEWIS KOHN & WALKER LLP
Nice Classes
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography (PET) or single photon emission tomography (SPECT), target radionuclide and peptide receptor radionuclide therapy (PRRT); theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumors; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET); radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; radiopharmaceuticals for use with high-sensitivity molecular imaging technologies such as PET (positron emission tomography) or SPECT (single photon emission tomography), for imaging organs and lesions and for early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumor diseases
Class 10
Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; control, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators for radiopharmaceutical purposes
Class 42
Conducting clinical trials in all stages and with various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)
Class 44
Medical services, in particular services in the field of radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapy, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy (PRRT), personal nuclear medicine and precision oncology
History of USPTO decisions and trademark events.
12 publications found
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
05/19/2022
REGISTERED-PRINCIPAL REGISTER
11/02/2021
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/17/2021
PUBLISHED FOR OPPOSITION
08/17/2021
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/28/2021
APPROVED FOR PUB - PRINCIPAL REGISTER
07/13/2021
ASSIGNED TO EXAMINER
07/12/2021
NOTICE OF DESIGN SEARCH CODE E-MAILED
04/03/2021
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/02/2021
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
01/28/2021
TEAS VOLUNTARY AMENDMENT RECEIVED
01/28/2021
NEW APPLICATION ENTERED
01/07/2021
Continuous trademark protection
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.